LONDON (Alliance News) - e-Therapeutics PLC on Wednesday said Development Director Steve Self will leave at the end of September, following a strategic refocus by the drug discovery company.
"Steve joined e-Therapeutics in December 2010 following a distinguished career at The Wellcome Foundation, Boots Healthcare and as R&D Director of Merck's Generic Global business. We thank him for his significant contribution to our activities and wish him continuing success in his new endeavours," said Executive Chairman Iain Ross in a statement.
Shares in e-Therapeutics were untraded Wednesday afternoon. They last closed at 10.56 pence.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.


(Sharecast News) - RNAi medicines data and development specialist e-Therapeutics proposed a fundraise and its delisting from AIM on Wednesday.


(Alliance News) - e-Therapeutics PLC on Wednesday announced its intention to cancel its admission to AIM and instead explore the option of listing on ...


e-Therapeutics PLC - Oxford, England-based computer-based drug discovery company - Says 2023 was